PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of neuroncolAboutAuthor GuidelinesEditorial BoardNeuro-Oncology
 
Neuro Oncol. 2009 August; 11(4): 423–429.
PMCID: PMC2743222

First report on a prospective trial with yttrium-90–labeled ibritumomab tiuxetan (Zevalin) in primary CNS lymphoma

Abstract

Most patients with primary CNS lymphoma (PCNSL) relapse after primary therapy. Standard salvage treatment has not yet been established in PCNSL. Anti-CD20 immunotherapy has expanded treatment options in systemic B-cell lymphoma; however, its use is limited by reconstitution of the blood–brain barrier after tumor shrinkage. The aim of this phase II trial was to evaluate the therapeutic efficacy, toxicity, and biodistribution of yttrium-90 (90Y) ibritumomab tiuxetan in PCNSL. Ten patients with relapsed PCNSL were included in a phase II trial and treated with the 90Y-labeled anti-CD20 antibody ibritumomab tiuxetan. Nine patients actually received the planned radioimmunotherapy. In six patients, biodistribution of the antibody was measured by indium-111 (111In) ibritumomab tiuxetan whole-body scans and single-photon-emission CT (SPECT) of the brain. All patients were evaluated for toxicity and response at least 4 weeks after therapy. Four patients responded: one patient had a complete response lasting 30+ months, and three patients had short-lived responses of ≤4 weeks. Five patients progressed, and one patient did not receive treatment due to an infection prior to 90Y-antibody administration. Target accumulation of the antibody was demonstrated in four of the six patients examined by SPECT imaging with 111In ibritumomab tiuxetan. All patients experienced grade 3/4 hematotoxicity but no acute neurotoxicity. Penetration of a therapeutic antibody into PCNSL and significant clinical activity was shown. Because of limited response duration and considerable hematotoxicity, future investigations should focus on a multimodal approach with additional chemotherapy and preferably autologous stem cell support.

Keywords: 90Y ibritumomab tiuxetan, CNS lymphoma, imaging, PCNSL, Zevalin

Primary CNS lymphoma (PCNSL) is a rare type of usually aggressive B-cell non-Hodgkin’s lymphoma exclusively involving the CNS. Standard salvage therapy has not yet been established. Despite remission of PCNSL after primary therapy in the majority of patients, relapse occurs within 1–2 years in 30%–60% of patients, with a median survival after relapse of only 2–4 months.1

The anti-CD20 monoclonal antibody rituximab expanded treatment options in systemic B-cell lymphoma.2 The radiolabeled anti-CD20 antibody yttrium-90 (90Y) ibritumomab tiuxetan (Zevalin, Bayer Schering Pharma, Berlin, Germany) has demonstrated efficacy in systemic lymphomas even refractory to chemotherapy and rituximab, with only one treatment course needed.3 Due to the large molecular size of 145 kDa, rituximab poorly penetrates the blood–brain barrier (BBB),4 which limits its use in PCNSL. According to PET, the BBB is initially leaky in PCNSL and reconstitutes after therapy-induced tumor shrinkage within 5 weeks.5 Therefore, a sufficient amount of 90Y ibritumomab tiuxetan (148 kDa) might be delivered to the tumor bulk in one treatment course.

The aim of this study was to evaluate the therapeutic efficacy, tumor penetration, and toxicity of 90Y ibritumomab tiuxetan in recurrent PCNSL.

Patients and Methods

Study Design

We planned to treat 10 patients with relapsed or refractory PCNSL in this phase II study. Primary end points were overall response and ibritumomab tiuxetan biodistribution; secondary end points were response duration, survival, and toxicity, including late neurotoxicity.

Inclusion criteria were histologically confirmed relapsed PCNSL after at least one prior treatment, age ≥ 18 years, KPS ≥ 60, and human immunodeficiency virus (HIV) negativity. Exclusion criteria were evidence of systemic lymphoma, active infection, severe concomitant disease, inadequate cardiac, liver, and kidney function, and abnormal hematological parameters.

The study was approved by the local ethics committee, and informed consent was obtained from all patients.

90Y ibritumomab tiuxetan therapy

An infusion of rituximab at 250 mg/m2 was given 8 days and 4 h before 90Y ibritumomab tiuxetan therapy to improve biodistribution of the radiolabeled antibody by binding to peripheral CD20+ B-cells. 90Y ibritumomab tiuxetan was given intravenously according to the standard regimen.

Seven patients were simultaneously treated with dexamethasone (2–8 mg three times daily) for 1 month. No concomitant antineoplastic therapy was given to the patients.

Biodistribution and Tumor Uptake

To evaluate antibody uptake in PCNSL after systemic intravenous administration, a dosimetric measurement study with ibritumomab tiuxetan labeled with the gamma emitter indium-111 (111In) was performed in patients 1–6. These patients received 170–190 MBq of the gamma emitter after the first rituximab administration on day −8. On a SPECT/CT system (Hawkeye Millenium, GE Medical Systems, Slough, UK), whole-body scans and single-photon-emission CT (SPECT) were performed 1 h and 2–5 days thereafter. Regions of interest (ROIs) were drawn around the tumor regions that were localized by SPECT/CT performed on day −8 and/or pre-treatment brain MRI. The mean uptake values (counts/minute/pixel) were divided by the values determined in ROIs of the adjacent regions (background). The ratios were corrected for physical decay of 111In (see Fig. 2).

Fig. 2.
SPECT/CT (column 1) and SPECT images (columns 2–6) of patients 1–6, showing increasing uptake in the tumors of patients 3–5 up to 5 days after administration of 111In ibritumomab tiuxetan. Arrows indicates sites of tumors.

Response Evaluation

Response evaluation by contrast-enhanced MRI was scheduled before and 1 and 3 months after treatment as well as every 3 months thereafter in responders or if clinically indicated, according to the International PCNSL Collaborative Group criteria.6 Additional imaging by 18F-fluorodeoxyglucose-PET (FDG-PET) was performed in patient 9 before treatment and in patient 6 before and 1 month after treatment parallel to MRI.

Results

Patient Characteristics

Ten patients with median age of 53.5 years (range, 41–79 years) and median KPS scores of 80% were included. Histology, obtained at first diagnosis, revealed diffuse large-cell B-cell lymphoma in all patients except patient 10, who had low-grade B-cell lymphoma. Patients received a median of three previous therapies (range, 1 to 7), including five patients that received previous whole-brain irradiation. Patient characteristics are given in Table 1.

Table 1.
Patient characteristics

Nine patients received the intended antibody treatment; patient 4, with concomitant diabetes and steroid treatment, was withdrawn due to pulmonary aspergillosis diagnosed after the first rituximab application and SPECT imaging but before treatment with 90Y ibritumomab tiuxetan.

SPECT Imaging with 111In Ibritumomab Tiuxetan

Imaging with 111In ibritumomab tiuxetan was performed in patients 1–6. Pretreatment MR images of these patients are shown in Fig. 1. SPECT revealed no lymphoma uptake in patients 1 and 6. Patients 3–5 showed prominent uptake in the tumors (Fig. 2). In patient 2, tumor uptake was assessable only by ROI evaluation (Fig. 3).

Fig. 1.
Pretreatment MR images of patients 1–6, who received subsequent 111In ibritumomab tiuxetan imaging.
Fig. 3.
Increasing 111In ibritumomab tiuxetan uptake in the tumors demonstrated by increasing uptake ratios in patients 2–5 (all values corrected for physical decay of 111In). Abbreviations: Tm, tumor; BG, background; p.i., postinfusion (in hours). Uptake ...

Overall Response and Response Duration

Four of the nine evaluable patients responded to 90Y ibritumomab tiuxetan treatment: Two patients showed complete response (CR) along with brief neurological improvement (patient 6 [see Fig. 4] and patient 7); one of them concomitantly received steroids. FDG-PET, performed before treatment and 4 weeks thereafter, in patient 6 showed decreased but still detectable FDG uptake. MRI, performed due to neurological deterioration, detected relapse with new lesions distant to the original target within 4 weeks in both patients. Uncertain complete remission on MRI with minimal residual contrast enhancement and neurological improvement after termination of steroid treatment was found in patient 10 and has been confirmed more than 30 months post-treatment by MRI. Patient 2 had partial response (PR) on MRI 1 month after treatment, with disease progression 2 weeks thereafter. This patient was concomitantly treated with dexamethasone initiated before pretreatment MRI. Five patients had progressive disease.

Fig. 4.
MR image of cerebellar lesion in patient 6: sagittal slices of contrast-enhanced T1-weighted MRI tomograms before (a) and 1 month after (b) treatment with 90Y ibritumomab tiuxetan showing disappearance of the cerebellar lymphoma manifestation (arrows). ...

None of the patients with prominent tumor uptake in SPECT responded to treatment. Patient 2, with PR, had uptake assessable only by ROI evaluation, and patient 6, with CR, showed no uptake in SPECT. Results for individual patients are given in Table 2.

Table 2.
Treatment response, response duration, and toxicity grade referring to Common Terminology Criteria classification

Toxicity

All patients experienced hematotoxicity beginning 4 weeks after therapy. Grade 3/4 leukopenia was seen in seven of nine evaluable patients, and grade 3/4 thrombocytopenia in eight patients.

Patient 10 had grade 3 pneumonia during grade 3 leukopenia, and patient 1 died after pneumonia and sepsis with grade 4 leukopenia. Further toxicities included grade II stomatitis and thrombangitis obliterans in patient 2 and pulmonary aspergillosis prior to treatment with 90Y ibritumomab tiuxetan in patient 4 (see Table 2).

Discussion

Imaging with 111In ibritumomab tiuxetan provided evidence that the antibody is able to cross the BBB at this stage of disease and accumulates within the target area 48 h and more after application. Furthermore, four of nine patients showed clinical responses to treatment with 90Y ibritumomab tiuxetan.

In a series of four patients with PCNSL, Dietlein et al.7 were not able to detect accumulation of iodine-123 (123I)-labeled rituximab within the tumor on SPECT 1, 24, or 48 h after application. These time points were chosen based on quick in vivo dehalogenation of the compound and short physical half-life of 123I (13 h). In our study, however, we used a murine anti-CD20 antibody firmly conjugated to tiuxetan and 111In, which has a longer physical half-life (67 h). We postulate a delayed accumulation of the antibody in PCNSL in some patients due to remaining barrier function of the leaky BBB, demonstrated in patients 2 and 6 without assessable uptake (scan reading and uptake ratios) up to 6 days following administration but both showing at least PR. The clinical response in patients without uptake (especially in this small number of patients) is not surprising, because in larger imaging studies with other lymphomas a good correlation between nuclear medicine and clinical response could not always be shown. Iwamoto et al.8 investigated 111In ibritumomab tiuxetan uptake in six PCNSL patients and found a 10-fold higher median dose of radiation in the lymphoma compared with normal brain tissue. Scans were acquired for up to 7 days following injection of 111In ibritumomab tiuxetan. The median clearance half-life within the lymphoma in this small patient cohort was calculated to be 96 h (range, 17–180 h), but no data were given regarding the time of maximum uptake.

We have not performed dosimetry in our patients. Doses reported by Iwamoto et al.8 ranged from 2 to 1,818 cGy (median, 701 cGy) within the lymphoma and only 17–130 cGy (median, 70 cGy) in normal brain tissue. With respect to neurotoxicity, we would not expect these doses to cause significant neurotoxicity even in patients pretreated with whole-brain irradiation. Sakamoto et al.9 reported on the use of stereotactic irradiation with concomitant chemotherapy in a small cohort of patients with PCNSL after prior whole-brain irradiation. They observed clinical activity in the absence of acute neurotoxicity. This is indicative of the radiosensitivity of PCNSL even in the recurrent situation.

The penetration of large molecules such as antibodies into the brain is limited to bulky tumor areas with at least partially disrupted BBB. Therefore, areas with small tumor cell accumulations with an intact BBB not visualized by MRI, as must be suspected in PCNSL, might not be reached by the antibody. This could explain why the observed responses were extremely short-lived, with new lesions occurring distant of the target tumor.

One approach to reach lymphoma cells beyond the BBB is to deliver treatment after prior osmotic BBB disruption by intra-arterial mannitol infusion. However, this approach requires adequate experience and careful patient selection. Doolittle et al.10 report on four patients receiving rituximab and chemotherapy after prior BBB disruption. To our knowledge, no treatment with 90Y ibritumomab tiuxetan after BBB disruption has been reported thus far.

The toxicity observed was similar to that seen in other studies of 90Y ibritumomab tiuxetan, with thrombocytopenia and leukopenia occurring approximately 4 weeks after therapy. Patients need to be closely monitored for hematological toxicity and infection. Importantly, no acute neurotoxicity was observed.

To date, experience with 90Y ibritumomab tiuxetan in PCNSL is limited to a few case reports including combination treatment with temozolomide1013 and a small study of six patients with recurrent PCNSL including imaging with 111In ibritumomab tiuxetan.8

The present study is the largest so far to investigate 90Y ibritumomab tiuxetan treatment in PCNSL, demonstrating penetration into PCNSL along with significant clinical activity. In contrast to the study reported by Iwamoto et al.,8 we saw complete disappearance of the tumor lesion in three of our patients. However, responses in our heavily pretreated patient cohort were short, and relapses occurred distant to target lesions. Moreover, we observed considerable delayed hematotoxicity causing infectious complications and interfering with salvage treatment. Despite the evidence of tumor penetration, monotherapy with 90Y ibritumomab tiuxetan proved not to be sufficient for the treatment of recurrent PCNSL in our heavily pretreated patient cohort. Based on experiences with rituximab in high-grade lymphomas, combination of radioimmunotherapy with chemotherapy seems desirable. However, due to the observed hematotoxicity, such a multimodal approach would require autologous stem cell support.

References

1. DeAngelis LM. Primary CNS lymphoma: Treatment with combined chemotherapy and radiotherapy. J Neurooncol. 1999;43:249–257. [PubMed]
2. Coiffier B, Haioun C, Ketterer N, et al. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: A multicenter phase II study. Blood. 1998;92:1927–1932. [PubMed]
3. Witzig TE, Gordon LI, Cabanillas F, et al. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin’s lymphoma. J Clin Oncol. 2002;20:2453–2463. [PubMed]
4. Rubenstein JL, Combs D, Rosenberg J, et al. Rituximab therapy for CNS lymphomas: Targeting the leptomeningeal compartment. Blood. 2003;101:466–468. [PubMed]
5. Ott RJ, Brada M, Flower MA, et al. Measurements of blood-brain barrier permeability in patients undergoing radiotherapy and chemotherapy for primary cerebral lymphoma. Eur J Cancer. 1991;27:1356–1361. [PubMed]
6. Abrey LE, Batchelor TT, Ferreri AJ, et al. International Primary CNS Lymphoma Collaborative Group. Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma. J Clin Oncol. 2005;23:5034–5043. [PubMed]
7. Dietlein M, Pels H, Schulz H, et al. Imaging of central nervous system lymphomas with iodine-123 labeled rituximab. Eur J Haematol. 2005;74:348–352. [PubMed]
8. Iwamoto FM, Schwartz J, Pandit-Taskar N, et al. Study of radiolabeled indium-111 and yttrium-90 ibritumomab tiuxetan in primary central nervous system lymphoma. Cancer. 2007;110:2528–2534. [PubMed]
9. Sakamoto M, Oya N, Mizowaki T, et al. Initial experiences of palliative stereotactic radiosurgery for recurrent brain lymphomas. J Neuro-oncol. 2006;77:53–58. [PubMed]
10. Doolittle ND, Jahnke K, Belanger R, et al. Potential of chemo-immunotherapy and radioimmunotherapy in relapsed primary central nervous system (CNS) lymphoma. Leuk Lymphoma. 2007;48:1712–1720. [PubMed]
11. Shah JJ, Meredith R, Shen S, et al. Case report of a patient with primary central nervous system lymphoma treated with radioimmunotherapy. Clin Lymphoma Myeloma. 2006;7:236–238. [PubMed]
12. Pitini V, Baldari S, Altavilla G, Arrigo C, Naro C, Perniciaro F. Salvage therapy for primary central nervous system lymphoma with (90) Y-ibritumomab and temozolomide. J Neurooncol. 2007;83:291–293. [PubMed]
13. Ferrucci PF, Vanazzi A, Tesoriere G, et al. Cerebrospinal fluid diffusion of Zevalin after high-activity treatment and stem cell support in a patient affected by diffuse large B-cell non-Hodgkin’s lymphoma with central nervous system involvement. Ann Oncol. 2005;16:1710–1711. [PubMed]
14. CTCAE Common Terminology Criteria for Adverse Events version 30 Online Instructions and Guidelines. Available at https://webappsctep.nci.nih.gov/webobjs/ctc/webhelp/welcome_to_ctcae.htm Accessed May 11, 2009.

Articles from Neuro-Oncology are provided here courtesy of Society for Neuro-Oncology and Oxford University Press